(2026). To Evaluate Whether Pretreatment CA19‐9 and DUPAN‐2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer. Annals of Gastroenterological Surgery.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"To Evaluate Whether Pretreatment CA19‐9 and DUPAN‐2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer."
Annals of Gastroenterological Surgery 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"To Evaluate Whether Pretreatment CA19‐9 and DUPAN‐2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer."
Annals of Gastroenterological Surgery, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.